帕金森疾病,机体炎症 z-bo 2020-10-16 310

　　In the latest research report published in the international journal Brain, scientists from the University of Luxembourg and other institutions revealed the link between inflammation and specific gene mutations in Parkinson's disease patients. In this article, the researchers discovered two things. Such biomarkers can be used to assess the status and progression of Parkinson's disease.

　　Related research results indicate that anti-inflammatory drugs can be used to target the human immune system and affect disease progression (at least in some patients). Approximately 15% of Parkinson's disease cases are related to a known genetic background. Among them, mutations in Perkin and PINK1 genes are the most common causes. Therefore, revealing the cellular mechanisms altered by gene mutations may contribute to the development of new therapies. This is very important. In this study, the researchers analyzed the sera of 245 participants in two independent studies and found patients with circulating mitochondrial DNA (mtDNA) and interleukin-6 mutations in Perkin or PINK1. (IL-6) The level rises. Researchers found that lack of Parkin or PINK1 protein can cause damage to mitochondrial autophagy, and abnormal mitochondrial levels can induce the release of mitochondrial DNA, which in turn induces inflammation in patients.

　　He pointed out that it increases the level of IL-6 in the blood. After reaching the brain, IL-6 is believed to play a very important role in the development of neurodegenerative diseases. The results of this article show that the use of anti-inflammatory drugs to treat or may slow down the progression of Parkinson's disease patients. By studying the differences between patients with Parkin or PINK1 gene mutations on one chromosome (heterojunction) or two chromosomes, researchers can detect the level of systemic inflammation in the patient's blood. We found that certain genotype biomarkers may be indicators of Parkinson’s disease. Compared with heterozygous patients, patients with mutations in both chromosomes have higher IL-6 levels. However, compared with healthy controls, heterozygous The level of IL-6 is higher in patients with cohesion, while the level of -6 is significantly higher. Heterozygous mutations are effective in the early stages of Parkinson's disease. It may indicate that it may constitute a risk factor. Researchers can even monitor their bodies before these heterozygous carrier diseases develop. The level of IL-6 in serum is used for early detection of disease. Similarly, the level of circulating glandular DNA can be used as an effective marker of disease progression in heterozygous Parkin/PINK1 mutation carriers.

　　Finally, researcher Grunewald said that the research in this article has potential clinical application value and importance. Detection of biomarkers present in the patient's serum may help indicate disease progression. At the same time, the results of this article are expected to help the growth of researchers. New therapy for Parkinson's disease/Parkinson's disease-related patients with innate immune response.